Synergy Pharmaceuticals, Inc Common Stock
SGYP
SGYP was delisted on the 7th of March, 2019.
156 hedge funds and large institutions have $700M invested in Synergy Pharmaceuticals, Inc Common Stock in 2016 Q4 according to their latest regulatory filings, with 28 funds opening new positions, 56 increasing their positions, 46 reducing their positions, and 19 closing their positions.
62% more call options, than puts
Call options by funds: $10.3M | Put options by funds: $6.38M
47% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 19
22% more repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 46
5% more funds holding
Funds holding: 149 → 156 (+7)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
56% less capital invested
Capital invested by funds: $1.58B → $700M (-$879M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$64.1M |
| 2 |
Millennium Management
New York
|
+$9.56M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$7.84M |
| 4 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$5M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$4.01M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$8.79M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$7.57M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$6.29M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$4M |
| 5 |
EI
EAM Investors
Solana Beach,
California
|
-$2.9M |
SGYP Hedge Fund Activity: Q4 2016 in Review
156 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in Synergy Pharmaceuticals, Inc Common Stock (SGYP) for Q4 2016, worth a combined $700M — down 56% from $1.58B a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new SGYP positions and 19 closed out — a net gain of 9 holders — while 56 added to existing stakes and 46 trimmed.
The largest buyer was OrbiMed, adding an estimated $64.1M. The largest seller was Fidelity Investments, exiting entirely with an estimated $8.79M sold.
- 156 institutional investors held Synergy Pharmaceuticals, Inc Common Stock (SGYP) as of Q4 2016, up from 149 in Q3 2016.
- Funds reported $700M of Synergy Pharmaceuticals, Inc Common Stock stock for Q4 2016, down 56% quarter-over-quarter.
- 28 funds opened new Synergy Pharmaceuticals, Inc Common Stock positions in Q4 2016 and 19 closed out, a net change of +9 holders.
- The largest Synergy Pharmaceuticals, Inc Common Stock buyer in Q4 2016 was OrbiMed, an estimated $64.1M added.
- The largest Synergy Pharmaceuticals, Inc Common Stock seller in Q4 2016 was Fidelity Investments, an estimated $8.79M sold.
Based on aggregated 13F filings for Q4 2016.